Sun Pharma Advanced Research Company Limited (BOM:532872)

Market Cap	52.15B
Revenue (ttm)	611.35M
Net Income (ttm)	-3.89B
Shares Out	n/a
EPS (ttm)	-11.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	119,320
Average Volume	44,266
Open	151.50
Previous Close	151.50
Day's Range	151.50 - 162.70
52-Week Range	109.20 - 257.70
Beta	n/a
RSI	67.29
Earnings Date	May 21, 2025

About BOM:532872

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company’s products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which...

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 409
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532872

Financial Performance

In 2023, BOM:532872's revenue was 755.45 million, a decrease of -68.36% compared to the previous year's 2.39 billion. Losses were -3.87 billion, 74.0% more than in 2022.